In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide Vasoactive intestinal peptide (VIP, aviptadil) | Natural fragment Thymosin alpha-1 | |
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Natural fragment | |
| Area | Immune and antimicrobial | Immune and antimicrobial | |
| Evidence | |||
| Amount of evidence | 887 (plus 505 on natural levels, listed separately) | 1,450 (plus 251 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 29 (23 in people) | 54 (45 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 15 · 1 active8 more mention it but do not test it | 56 · 13 active9 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Vasoactive intestinal peptide (VIP, aviptadil) | Thymosin alpha-1 |
|---|---|---|
| Immune responseReproductive and sexual health | 301722 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
No FDA approval and no central EU authorisation (EMA).
No FDA approval and no central EU authorisation (EMA).
| Receptor activity and mechanismWhole body | 250411235 | 1025934 |
|---|
| MortalityWhole body | 44 | 947816 |
|---|
| Adverse eventsWhole body | 18144 | 5647441 |
|---|
| Inflammation markersRespiratory | 212712 | 110404129 |
|---|
| Tumor growthCancer | 236611 | 99273735 |
|---|
| Intensive care and hospital outcomesRespiratory | 99 | 3838 |
|---|
| Respiratory functionRespiratory | 4318817 | 1717 |
|---|
| Heart functionCardiovascular | 4918247 | 11 |
|---|
| PharmacokineticsReproductive and sexual health | 17710 | 3411212 |
|---|
| Sex hormones and fertilityReproductive and sexual health | 3441218 | 13319 |
|---|
| PainNervous system and cognition | 14131 | 66 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Thymosin alpha-1 is the same as Prothymosin alpha (human) residues 2 to 29, with 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Vasoactive intestinal peptide (VIP, aviptadil) | Thymosin alpha-1 |
|---|---|---|
| MortalityInfectionCompared as: difference from placebo, in rr | No comparable result 4 randomized-trial results measure it in another way or another unit. | 0.74 RR Relative risk of death n = 3612013 |
| Intensive care and hospital outcomesRespiratoryCompared as: value in the arm that got the peptide, in days | 7.8 days Time to discharge Placebo: 10 days n = 802025 | No comparable result 13 randomized-trial results measure it in another way or another unit. |
| Tumor growthCancerCompared as: value in the arm that got the peptide, in % | No randomized trial result 23 results from other study designs. | 83.3% One-year recurrence rate · group A, thymosin alpha-1 plus TACE n = 572004 |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 63% Primary safety outcome Placebo: 56% 3 daysn = 4612023 |
No comparable result
4 randomized-trial results measure it in another way or another unit.
0.74 RR
Relative risk of death
n = 3612013
No comparable result 27 randomized-trial results measure it in another way or another unit. |
Time to discharge
Placebo: 10 days
n = 802025
No comparable result
13 randomized-trial results measure it in another way or another unit.
No randomized trial result
23 results from other study designs.
83.3%
One-year recurrence rate · group A, thymosin alpha-1 plus TACE
n = 572004
63%
Primary safety outcome
Placebo: 56%
3 daysn = 4612023
No comparable result
27 randomized-trial results measure it in another way or another unit.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 15 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
National Institute of Allergy and Infectious Diseases (NIAID)473 participants20 Apr 2021 to 20 Nov 2022
Covid19
National Institute of Allergy and Infectious Diseases (NIAID)471 participants20 Apr 2021 to 20 Nov 2022
Covid19
APR Applied Pharma Research s.a.203 participants15 May 2020 to 22 Feb 2021
Critical COVID-19 With Respiratory Failure · Acute Respiratory Distress Syndrome (ARDS) · Corona Virus Infection · Acute Lung Injury
8 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 56 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Shanghai Jiao Tong University School of Medicine2,944 participants21 Jan 2020 to est. Jun 2020
2019 Novel Coronavirus Infection
Fudan University2,500 participants1 Apr 2021 to est. 31 Mar 2027
Stage II Colorectal Cancer · Stage III Colorectal Cancer
Sun Yat-sen University1,106 participants6 Sept 2016 to 23 Mar 2021
Sepsis
9 more mention it but do not test it. They only measure it or name it in their text.